Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • CDSCO Warning: Beware...

    CDSCO Warning: Beware of hacking risk in Medtronic insulin pumps

    Farhat NasimWritten by Farhat Nasim Published On 2019-07-04T11:40:57+05:30  |  Updated On 4 July 2019 11:40 AM IST
    CDSCO Warning: Beware of hacking risk in Medtronic insulin pumps

    New Delhi: Months after issuing an advisory against three models of pacemakers sold by the world’s largest medical device manufacturer, Medtronic, country's apex drug regulator CDSCO has now flagged an alert about insulin pumps manufactured by the US giant. CDSCO alert states that the company's MiniMed 508 Insulin Pump and MiniMed Paradigm Series Insulin Pumps have cybersecurity risks wherein someone other than the patient can wirelessly connect to them, change its settings and control the delivery.


    The alert comes seven days after the US health regulator (USFDA) issued a warning to patients and health care providers that certain Medtronic MiniMed insulin pumps are being recalled due to potential cybersecurity risks.


    Medical Dialogues had earlier reported that after pacemakers, insulin pumps by Medtronic had fallen under the U.S health regulatory scanner as the USFDA warned patients and health care providers that certain Medtronic MiniMed insulin pumps being recalled due to potential cybersecurity risks and recommends that patients using these models switch their insulin pump to models that are better equipped to protect against these potential risks.


    Also Read: USFDA Warning: Medtronic recalls insulin pumps over cybersecurity vulnerabilities


    Prior to this CDSCO had red-flagged three brands of pacemakers manufactured by US-based medical device maker Medtronic. As per the USFDA alert, three medical device reports in the USA, in which a Medtronic implantable pacemaker or cardiac resynchronization therapy pacemakers (CRT-P) battery had fully drained because of a crack in the device’s capacitator, without any warning to the patients or health care providers.


    Also Read: Red Flag: CDSCO warns against Medtronic pacemaker for battery related malfunction


    Raising yet another concern, CDSCO has now issued an alert related to the insulin pumps manufactured by Medtronic's that could enable a person to overdose the patient with insulin, leading to low blood sugar(hypoglycemia), or to stop insulin delivery, leading to high blood sugar and diabetic ketoacidosis (a buildup of acids in the blood).


    "Security researchers have identified potential cybersecurity vulnerabilities related to these insulin pumps. Any unauthorised person with special technical skills and equipment could potentially connect wirelessly to a nearby insulin pump and change the pump's settings and control the delivery," the Central Drugs Standard Control Organisation (CDSCO) said in its alert.


    The CDSCO has advised healthcare professionals, distributors and users and staff involved in the management of patients to check and see if the model and the software version of their insulin pump is affected. It has advised them to monitor blood glucose levels closely and immediately cancel any unintended boluses.


    It also advised not to share the pump serial number, be attentive to pump notifications, alarms and alerts and connecting the Medtronic insulin pump in use to other Medtronic devices and software only.


    The CDSCO stated that it has not received any complaints from the market on the issue nor is it aware of any confirmed reports of patient harm related to these potential cybersecurity risks.

    blood sugarCDSCOcdsco warningCentral Drugs Standard Control Organisationcyber securitydiabetesgovt advisoryhacking riskinsulin pumpsMedtronicMiniMedMiniMed insulin pumpsMiniMed Paradigm seriespacemakersred alertUS firm
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok